WORST OF BARRIER REVERSE CONVERTIBLE LINKED TO WORST OF - NOVARTIS N/BAYER/SANOFI Share Price

Certificat

KPGDDU

CH1305181922

Market Closed - Swiss Exchange 16:20:00 26/06/2024 BST
92.65 CHF -0.27% Intraday chart for WORST OF BARRIER REVERSE CONVERTIBLE LINKED TO WORST OF - NOVARTIS N/BAYER/SANOFI
1 month-4.09%
3 months-3.79%
Date Price Change
26/06/24 92.65 -0.27%
25/06/24 92.9 -0.05%

Delayed Quote Swiss Exchange

Last update June 26, 2024 at 04:20 pm

More quotes

Static data

Product typeObligations Convertibles
Buy / SellCALL
Underlying NOVARTIS AG
Issuer UBS
KPGDDU
ISINCH1305181922
Date issued 06/12/2023
Strike 84.89 CHF
Maturity 08/12/2025 (525 Days)
Parity 1 : 1
Emission price 100 CHF
Emission volume N/A
Settlement règlement en espèces
Currency CHF

Technical Indicators

Highest since issue 105.2 CHF
Lowest since issue 91.55 CHF
Spread 10 CHF
Spread %1.08%

Company Profile

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
-
More about the company

Ratings for Novartis AG

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Novartis AG

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
107 USD
Average target price
110.3 USD
Spread / Average Target
+3.05%
Consensus
  1. Stock Market
  2. Certificates
  3. KPGDDU Certificat